L&C Bio Co., Ltd
KOSDAQTotal Valuation
L&C Bio Co., Ltd carries a market capitalization of 1.92T, placing it among publicly traded companies globally. Its enterprise value stands at 1.64T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.92T |
| Enterprise Value | 1.64T |
Valuation Ratios
L&C Bio Co., Ltd trades at a trailing price-to-earnings ratio of 16.02. The price-to-sales ratio is 16.22, and the price-to-book ratio stands at 14.06.
| PE Ratio | 16.02 |
| PS Ratio | 16.22 |
| PB Ratio | 14.06 |
| P/TBV Ratio | 18.61 |
| P/FCF Ratio | 37.54 |
| P/OCF Ratio | 82.02 |
Enterprise Valuation
On an enterprise value basis, L&C Bio Co., Ltd trades at an EV/EBITDA multiple of 154.69 and an EV/FCF ratio of 38.70. The EV/Sales ratio of 16.72 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 154.69 provides insight into valuation relative to core operating earnings.
| EV / Sales | 16.72 |
| EV / EBITDA | 154.69 |
| EV / EBIT | 154.69 |
| EV / FCF | 38.70 |
Financial Position
L&C Bio Co., Ltd maintains a current ratio of 0.64, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.64 |
| Quick Ratio | 0.20 |
| Debt / Equity | 41.03 |
| Debt / EBITDA | 8.25 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -74.01 |
| Return on Assets (ROA) | -30.06 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -45.69 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.99 |
Taxes
Over the trailing twelve months, L&C Bio Co., Ltd has paid -21.16B in income taxes, reflecting an effective tax rate of 9.51.
| Income Tax | -21.16B |
| Effective Tax Rate | 9.51 |
Stock Price Statistics
L&C Bio Co., Ltd's stock has gained approximately 154.72313% over the past 52 weeks. The 50-day moving average sits at 75,266.00, while the 200-day moving average is 68,806.25.
| Beta (5Y) | N/A |
| 52-Week Price Change | 154.72313% |
| 50-Day Moving Average | 75,266.00 |
| 200-Day Moving Average | 68,806.25 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, L&C Bio Co., Ltd generated 98.10B in revenue and converted that into -135.14B in net income, yielding earnings per share of -5,720.08. EBITDA reached 10.60B, while operating income came in at 10.60B.
| Revenue | 98.10B |
| Gross Profit | 53.99B |
| Operating Income | 10.60B |
| Pretax Income | -156.40B |
| Net Income | -135.14B |
| EBITDA | 10.60B |
| EBIT | 10.60B |
| Earnings Per Share (EPS) | -5,720.08 |
Balance Sheet
L&C Bio Co., Ltd holds 48.64B in cash and equivalents against 87.49B in total debt, resulting in a net debt position of 43.64B. Total book value stands at 113.19B, with working capital of -88.75B providing operational flexibility.
| Cash & Cash Equivalents | 48.64B |
| Total Debt | 87.49B |
| Net Debt | 43.64B |
| Equity (Book Value) | 113.19B |
| Book Value Per Share | 4,787.49 |
| Working Capital | -88.75B |
Cash Flow
L&C Bio Co., Ltd produced 19.40B in operating cash flow over the past twelve months. After subtracting -22.99B in capital expenditures, free cash flow totaled -3.59B - equivalent to -151.89 per share.
| Operating Cash Flow | 19.40B |
| Capital Expenditures | -22.99B |
| Free Cash Flow | -3.59B |
| FCF Per Share | -151.89 |
Margins
L&C Bio Co., Ltd operates with a gross margin of 55.03, reflecting its pricing power and cost economics. The operating margin of 10.81 and net profit margin of -137.76 provide insight into operational efficiency.
| Gross Margin | 55.03 |
| Operating Margin | 10.81 |
| Pretax Margin | -159.43 |
| Profit Margin | -137.76 |
| EBITDA Margin | 10.81 |
Dividends & Yields
The company's payout ratio of 0.00 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.03 |
| Dividend Yield | N/A |
| Payout Ratio | 0.00 |
| Shareholder Yield | -2.00 |
| FCF Yield | 2.66 |
Stock Splits
L&C Bio Co., Ltd's most recent stock split took place on October 12, 2020 with a 1:3 split ratio.
| Last Split Date | 10/12/2020 |
| Split Ratio | 1:3 |
Scores
L&C Bio Co., Ltd posts an Altman Z-Score of 4.25, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.25 |